Somatic BRCA2 bi-allelic loss in the primary prostate cancer was associated to objective response to PARPi in a sporadic CRPC patient
N Romero-Laorden, E Piñeiro-Yañez… - Annals of …, 2017 - annalsofoncology.org
Recent next generation sequencing (NGS) studies conducted in primary tumours and
metastatic castration-resistant prostate cancer (mCRPC) have identified a prevalence of
germline and somatic defects in DNA repair genes higher than expected, particularly in the
BRCA2 gene [1]. Germline mutations and somatic defects identified in the metastases of
mCRPC patients have been associated with the response to the PARP inhibitor (PARPi)
olaparib and carboplatin [2, 3]. Here we report the remarkable radiologic and biochemical …
metastatic castration-resistant prostate cancer (mCRPC) have identified a prevalence of
germline and somatic defects in DNA repair genes higher than expected, particularly in the
BRCA2 gene [1]. Germline mutations and somatic defects identified in the metastases of
mCRPC patients have been associated with the response to the PARP inhibitor (PARPi)
olaparib and carboplatin [2, 3]. Here we report the remarkable radiologic and biochemical …